EBioMedicine · 2026
Quantifying rate-limiting genetic variation in breast and ovarian tumourigenesis.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Houlahan Kathleen E, Bihie Mahad, Greatti Yves, Contreras Julián Grandvallet, Fulop Daniel J, Lopez Gonzalo, Williams Marc, Huang Hsin-Hsiung, Van Loo Peter, Boutros Paul C, Huang Kuan-Lin
Аннотация
BACKGROUND: The number and type of genetic alterations required to initiate breast and ovarian cancer remain unclear. While germline BRCA1/2 carriers show markedly elevated cancer risk, it is uncertain whether point mutations or copy number alterations constitute the rate-limiting events of tumourigenesis.
METHODS: We developed a statistical framework extending prior incidence-mutation models to estimate the minimal number and type of driver events required for cancer initiation. Somatic mutation and copy-number data from >3000 breast and ovarian cancers in TCGA and METABRIC were compared between germline BRCA1/2 carriers and non-carriers matched on subtypes. Results were validated through analyses of evolutionary timing data, as well as single-cell whole genome sequencing (scWGS) data of genetically-engineered and patient-derived cancer/pre-cancerous cells.
FINDINGS: Deletions, rather than single-nucleotide variants (SNVs), emerged as the likely rate-limiting events. Modeling indicated that 1-3 deletions are sufficient to initiate tumourigenesis, whereas SNVs alone could not explain observed incidence ratios. BRCA1/2-driven and sporadic tumours converged on similar deletion profiles, including early recurrent deletions of chromosomes 13q and 17, though carriers accumulated them more rapidly.
INTERPRETATION: Deletion-associated chromosomal instability likely represents the central trigger for breast and ovarian cancer initiation. These results explain why certain somatic driver mutations detected in normal tissues may not predict malignant progression, and that early detection strategies should instead prioritize testing deletions as potential biomarkers.
FUNDING: NIH/NCI (P30CA016042; 1U01CA214194-01), NIH NIGMS (R35GM138113, 2R35GM138113), ACS (RSG-22-115-01-DMC), CIHR Vanier Fellowship, and the Francis Crick Institute with core funding from Cancer Research UK, UK Medical Research Council, and Wellcome Trust.
METHODS: We developed a statistical framework extending prior incidence-mutation models to estimate the minimal number and type of driver events required for cancer initiation. Somatic mutation and copy-number data from >3000 breast and ovarian cancers in TCGA and METABRIC were compared between germline BRCA1/2 carriers and non-carriers matched on subtypes. Results were validated through analyses of evolutionary timing data, as well as single-cell whole genome sequencing (scWGS) data of genetically-engineered and patient-derived cancer/pre-cancerous cells.
FINDINGS: Deletions, rather than single-nucleotide variants (SNVs), emerged as the likely rate-limiting events. Modeling indicated that 1-3 deletions are sufficient to initiate tumourigenesis, whereas SNVs alone could not explain observed incidence ratios. BRCA1/2-driven and sporadic tumours converged on similar deletion profiles, including early recurrent deletions of chromosomes 13q and 17, though carriers accumulated them more rapidly.
INTERPRETATION: Deletion-associated chromosomal instability likely represents the central trigger for breast and ovarian cancer initiation. These results explain why certain somatic driver mutations detected in normal tissues may not predict malignant progression, and that early detection strategies should instead prioritize testing deletions as potential biomarkers.
FUNDING: NIH/NCI (P30CA016042; 1U01CA214194-01), NIH NIGMS (R35GM138113, 2R35GM138113), ACS (RSG-22-115-01-DMC), CIHR Vanier Fellowship, and the Francis Crick Institute with core funding from Cancer Research UK, UK Medical Research Council, and Wellcome Trust.